Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 26Genitourinary 16Plasma cell 10Thoracic 4Gastrointestinal 4Sarcoma 3Head & Neck 3Other solid neoplasm 2Lymphoid 2Gynecologic 2Endocrine 2Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 2

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Denosumab × Dermatologic × Clear all
NCT03620019 2026-03-27

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
25 enrolled 16 charts
Dermatologic

Melanoma

NCT03161756 2022-04-07

CHARLI

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Unknown
72 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡